key: cord-0852364-y36ahx92
authors: Suhandynata, Raymond T; Hoffman, Melissa A; Huang, Deli; Tran, Jenny T; Kelner, Michael J; Reed, Sharon L; McLawhon, Ronald W; Voss, James E; Nemazee, David; Fitzgerald, Robert L
title: Commercial Serology Assays Predict Neutralization Activity Against SARS-CoV-2
date: 2020-10-21
journal: Clin Chem
DOI: 10.1093/clinchem/hvaa262
sha: d15853175c34b84579fbd07677e24febb2f7ecb5
doc_id: 852364
cord_uid: y36ahx92

BACKGROUND: It is unknown whether a positive serology result correlates with protective immunity against SARS-CoV-2. There are also concerns regarding the low positive predictive value of SARS-CoV-2 serology tests, especially when testing populations with low disease prevalence. METHODS: A neutralization assay was validated in a set of PCR confirmed positive specimens and in a negative cohort. In addition, 9,530 specimens were screened using the Diazyme SARS-CoV-2 IgG serology assay and all positive results (N = 164 individuals) were reanalyzed using the neutralization assay, the Roche total immunoglobin assay, and the Abbott IgG assay. The relationship between the magnitude of a positive SARS-CoV-2 serology result and neutralizing activity was determined. Neutralizing antibody titers (ID50) were also longitudinally monitored in SARS-CoV-2 PCR confirmed patients. RESULTS: The SARS-CoV-2 neutralization assay had a positive percent agreement (PPA) of 96.6% with a SARS-CoV-2 PCR test and a negative percent agreement (NPA) of 98.0% across 100 negative control individuals. ID50 neutralization titers positively correlated with all three clinical serology platforms. Longitudinal monitoring of hospitalized PCR confirmed COVID-19 patients demonstrated they made high neutralization titers against SARS-CoV-2. PPA between the Diazyme IgG assay alone and the neutralization assay was 50.6%, while combining the Diazyme IgG assay with either the Roche or Abbott platforms increased the PPA to 79.2% and 78.4%, respectively. CONCLUSIONS: These three clinical serology assays positively correlate with SARS-CoV-2 neutralization activity observed in COVID-19 patients. All SARS-CoV-2 PCR positive patients develop neutralizing antibodies.

The 2019 coronavirus pandemic is caused by the highly pathogenic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that was first discovered in Wuhan, China (1, 2) . As governments across the world struggle to contain the spread of the virus, the worldwide economy has been impacted by the resulting shutdown and social distancing protocols that have been implemented (3) (4) (5) (6) (7) . As nations begin to "re-open their economies" in stages, a major question that surrounds COVID-19 antibody testing is whether SARS-CoV-2 serology tests can be used to identify individuals with protective immunity against the virus (8) . Neutralizing antibodies play a key role in the quest for protective immunity against SARS-CoV-2 (9) , and ID50 neutralization titers have been the reference method to assess protective immunity against smallpox, polio, and influenza viruses following vaccine administration (10) (11) (12) . A number of reports have characterized the clinical performance of commercially available SARS-CoV-2 serology assays (13) (14) (15) (16) (17) (18) (19) (20) . However, whether commercial SARS-CoV-2 serology platforms correlate with the presence of neutralizing antibodies and protective immunity against COVID-19 still needs further exploration (21-27).

A recent comparison of six SARS-CoV-2 immunoassays and a microneutralization assay against SARS-CoV-2 (28) demonstrated that 41 of 62 COVID-19 patients showed neutralizing antibodies. Here we evaluated the clinical sensitivity and specificity of a pseudovirus based neutralization assay and investigated the correlation between the neutralization assay (29, 30) and SARS-CoV-2 serology platforms in a large cohort of clinical specimens. We determined the orthogonality of the Diazyme, Roche, and Abbott assays to initiate a dual immunoassay approach for confirming positive SARS-CoV-2 serology results, as suggested by the Centers for Disease Control and Prevention (31) . This screen and confirm approach was applied retrospectively to 9,530 SARS-CoV-2 tests, demonstrating that combining two orthogonal serology assays substantially improved the predictive value for identifying neutralizing antibodies.

The patient cohorts used in this study are illustrated in Figure 1 . Briefly, the main cohort ( Figure 1A) consisted of 9,530 consecutive specimens (K-EDTA, lithium-heparin plasma separator tubes, and/or serum separator tubes) that were screened at UC San Diego Health using the Diazyme IgG assay from 4/14/20 until 6/12/20. The specimens that were positive using the Diazyme IgG assay (N=164 specimens, N=164 individuals) were separated into subgroups depending on symptoms, if they were admitted, or if they were from a skilled nursing facility. All of the specimens that screened positive with the Diazyme assay were retrospectively tested using the neutralization, Roche, and Abbott assays. A separate cohort ( Figure 1B ) was used to evaluate the relationship between hospitalized SARS-CoV-2 PCR confirmed positive patients (31 patients, 87 specimens) and the neutralization assay. The last cohort ( Figure 1C ) was used to evaluate the relationship between SARS-CoV-2 negative specimens (100 specimens from 100 individuals) and the neutralization assay. The negative cohort consisted of 7 patients positive for other coronaviruses (229E, HKU1, NL63, or OC42), 4 Rhinovirus positive patients, 10 apparently healthy individuals, and 79 COVID-19 naïve specimens (individual patients collected in 2018, stored -20 o C).

The group (N=251 specimens, N=195 individuals) used to evaluate a cutoff for neutralization activity on each of the commercial serology platforms, shown in Figure 5 , included the 164 specimens from 164 individuals that were seropositive for IgG on the Diazyme platform and the 87 specimens from the 31 SARS-CoV-2 PCR confirmed patients (that were also positive on the Diazyme IgG assay). The median number of days post PCR positivity for these 87 specimens from 31 patients was 9 days, with an interquartile range of 5 -15 days. The median number of days post-symptom onset for these specimens 5 was 13 days, with an interquartile range of 9 -18 days. Specimens were split into two groups (Negative and Positive) based on the absence or presence of SARS-CoV-2 neutralization activity.

All patient specimens were collected under UCSD IRB protocol 181656.

Individuals were classified into three groups based on symptom severity. Asymptomatic individuals had no COVID-19 related symptoms (shortness of breath, fever, cough, loss of taste, diarrhea etc.) Mildly symptomatic individuals had mild COVID-19 related symptoms (as above), and did not require hospital admission. Admitted patients had COVID-19 related symptoms and were admitted to the hospital due to the severity of their symptoms upon presentation.

All 31 SARS-CoV-2 patients were positively confirmed for COVID-19 by an emergency use authorized nucleic acid test that had also been validated in our laboratory (Abbott ID NOW, GenMark ePlex, Abbott RealTime, Roche cobas 6800) (13, 20) . The Abbott RealTime and cobas 6800 are RT-PCR based tests, while the Abbott ID Now and GenMark ePlex are nucleic acid amplification based tests. For simplicity these patients will be referred to as SARS-CoV-2 PCR confirmed patients.

Serology was performed on the Diazyme DZ-Lite 3000 plus clinical analyzer as previously described for IgG (13) . Serology was performed on the Roche Cobas 8000 e801 analyzer (Roche Elecsys Anti-SARS-CoV-2 total Ig) and the Abbott ARCHITECT i1000SR analyzer (Abbott SARS-CoV-2 IgG) according to the signal of sample/cutoff); values ≥ 1.00 COI are considered reactive. The Abbott platform reports results in the form of an Index value (S/C); Index values ≥ 1.4 S/C are considered reactive. For consistency, we refer to reactive and non-reactive to mean the same as positive and negative throughout this report.

The neutralization assays were performed as previously described using a pseudovirus (PSV) (30) . The PSV assay was established for both SARS-CoV-1 and SARS CoV-2 using murine leukemia virus-based PSV.

The assay used single cycle infectious viral particles containing firefly luciferase. The amount of luminescence in HeLa cells that stably expressed the cell surface receptor angiotensin converting enzyme 2 were measured after viral infection. Titers of 50% inhibitory dilution (ID50) were determined.

An ID50 titer of greater than or equal to 50 was considered a positive neutralization result. The PSV assay was compared with a live replication-competent virus and neutralizing antibodies identified with the assay provided protection against high dose SARS-CoV-2 infection in a hamster animal model (29) .

All neutralization studies were conducted in a blinded manner.

The respiratory pathogen nucleic acid test was performed as previously described to confirm patients with other respiratory pathogens (13) .

Positive percent agreement (PPA) between the Diazyme IgG and Roche assay was calculated by taking the 164 Diazyme IgG screened positives and subsequently testing them on the Roche platform.

Specimens that were positive on the Roche were treated as in agreement and specimens that were negative on the Roche were treated as not in agreement. The PPA was defined as:

This was done in the same manner for calculating PPA between the Diazyme IgG and Abbott assays.

PPA between the neutralization assays and the Diazyme IgG assay was calculated by taking the 164 Diazyme IgG screened positives and testing them for the presence of neutralizing antibodies. Specimens with ID50 neutralization titers >50 were treated as in agreement and specimens with ID50 neutralization titers <50 were treated as not in agreement, and the PPA is defined as above.

Negative percent agreement (NPA) between the neutralization assays and the Diazyme IgG assay was calculated by testing specimens from 100 SARS-CoV-2 PCR negative individuals ( Figure 1C ) for the presence of neutralizing antibodies. Specimens with ID50 neutralization titers <50 were treated as in agreement and specimens with ID50 neutralization titers >50 were treated as not in agreement. The NPA was then defined as:

Data was analyzed using R in Rstudio and linear regression analysis for all figures were performed in excel or Rstudio. Box and whisker plots were generated in Rstudio. Mann-Whitney and Fishers exact test were performed in R for the box and whisker plots and demographics table, respectively.

Demographics of the Diazyme IgG seropositive individuals, which were divided based on symptom severity, are shown for age, gender, body mass index, ethnicity, underlying medical conditions, PCR positivity for COVID-19, and positivity for neutralization activity against SARS-CoV-2 in Table 1 was observed across all three groups for the presence of neutralization activity against SARS-CoV-2, with 98% of admitted patients having neutralization activity vs 19% in the asymptomatic group.

Demographics for the 44 Diazyme IgG seropositive patients and staff from skilled nursing facilities could not be retrieved because they were de-identified prior to analysis.

The SARS-CoV-2 neutralization assay detected neutralization activity in 96.6% of specimens from SARS-CoV-2 PCR confirmed patients, and in 2.0% of the SARS-CoV-2 negative specimens (Figure 2) . 83.9% of the specimens from SARS-CoV-2 PCR confirmed patients and 14.0% of the SARS-CoV-2 negative specimens had SARS-CoV-1 neutralization activity (Figure 2) . SARS-CoV-1 or SARS-CoV-2 neutralization was not detected in 7 patients infected with non-COVID-19 coronaviruses and 4 patients infected with rhinovirus (Supplementary Table 1 ).

Linear regression analysis was performed to evaluate the relationship between ID50 neutralization titers and three commercially available SARS-CoV-2 serology platforms for PCR confirmed patients (Supplementary Figure 1) . All three platforms showed positive correlation to SARS-CoV-2 ID50 titers.

SARS-CoV-2 ID50 neutralization titers were longitudinally monitored in 13 PCR confirmed SARS-CoV-2

patients. Serial sampling revealed that SARS-CoV-2 ID50 neutralization titers increased with disease progression in 11 of the 13 patients, while the remaining two patients maintained ID50 neutralization titers of ≥ 1000 (Figure 3) . Once elevated, neutralization titers appeared to reach a plateau that stayed elevated up to 25 days (longest time tested). Notably, all patients developed high titers by two weeks after becoming PCR positive.

The 164 Diazyme screened IgG seropositive patient specimens were also analyzed on the Roche Total Ig and Abbott IgG SARS-CoV-2 serology platforms. The overall positive percent agreement (PPA) between the Diazyme IgG assay and the Roche total Ig or Abbott IgG assays were 58.5% and 59.1%, respectively (Supplementary Figure 2) . The PPA between Diazyme and Roche was 20.6% for asymptomatic individuals, 71.7% for patients with mild symptoms, 90.9% for admitted patients, and 90.9% for patients/staff from skilled nursing facilities ( Figure 4A) . The PPAs between Diazyme and Abbott were similar to what was observed with the Roche assay ( Figure 4A) . The percentage of individuals with detectable levels of SARS-CoV-2 neutralization activity in the asymptomatic, mild, admitted, and skilled nursing facility groups ( Figure 4B ) closely mirror the observed PPAs between the Diazyme IgG and

Roche/Abbott platforms for each respective group (Figure 4A) . In contrast, the percentage of individuals with detectable levels of SARS-CoV-1 neutralization activity decreased with increasing PPA between serology platforms ( Figure 4B) . Overall, 50.6% of Diazyme IgG seropositive individuals (N=164) had detectable neutralization activity, from which a total of 96 and 93 of these individuals were also seropositive on the Roche and Abbott platforms, respectively ( Figure 4C) . The percentage of specimens that were positive on two serology platforms that had neutralization activity was 79.2% and 78.4% when using the Diazyme + Roche and Diazyme + Abbott, respectively ( Figure 4C) . Confidence intervals for SARS-CoV-2 ID50 titers across the four different populations that were tested demonstrated significant overlap (Supplementary Table 2 ). All specimens from PCR confirmed positive patients with a positive serology result by either the Diazyme IgG (N=71), Roche total Ig (N=76), and Abbott IgG (N=75) assays had neutralization activity (>ID50).

Boxplots of the observed responses (AU/mL, COI, S/C) on the Diazyme, Roche, and Abbott platforms, 98.8% for Diazyme, 95.1% for Abbott, and 83.5% for Roche.

The SARS-CoV-2 neutralization assay had a PPA of 96.6% with a SARS-CoV-2 PCR test (N=87 specimens, N=31 patients) and a negative percent agreement (NPA) of 98.0% across 100 negative control subjects.

Interestingly, 83.9% of specimens from SARS-CoV-2 PCR confirmed patients had neutralizing activity for SARS-CoV-1, which was responsible for IgG assay had the strongest correlation with SARS-CoV-2 neutralization titers, and could be a result of the linear characteristics of this platform (13) . Furthermore, all platforms were highly sensitive for the detection of ID50 neutralization titers greater than 1000 (Supplementary Figure 1) . At ID50 titers of greater than 1000, 98.9% of the specimens were seropositive on the Diazyme IgG assay, and 100% of the specimens were seropositive for both the Roche and Abbott platforms. Longitudinal monitoring of SARS-CoV-2 ID50 neutralization titers in PCR confirmed SARS-CoV-2 PCR positive hospitalized patients revealed that all patients developed robust neutralization titers during the course of infection (Figure 3 ).

Using the Roche or Abbott SARS-CoV-2 serology platforms to confirm specimens initially screened positive on the Diazyme IgG assay demonstrated that nearly 40% of the 164 IgG seropositive individuals would have been classified as false positives by the confirmatory assay. As predicted previously (13) , the percentage of individuals that were retrospectively identified as falsely positive depended greatly on the population of individuals being tested. The retrospective false positive rate was as high as 79.4% in asymptomatic individuals, approximately 30% in individuals with mild symptoms, and potentially 0% in admitted patients. One limitation with using a secondary platform to confirm SARS-CoV-2 seropositive specimens, is that there is no reference assay for COVID-19 serology at this time. Based on prevalence and specificity of this assay it is likely that the discordant specimens observed are false positives, but prudent practice would be to call these specimens indeterminate and ask for repeat testing. Altogether, this emphasizes the effect of disease prevalence on the positive predictive values, and highlights the danger of screening low prevalence populations even when using a highly specific SARS-CoV-2 serology assay.

100% of specimens that tested positive on all three commercially available serology platforms had detectable ID50 titers (> 50) against SARS-CoV-2. In contrast, only 50.6% of the 164 seropositive individuals identified on the Diazyme platform had neutralization titers (Figure 4C) , a percentage similar to the PPA between Diazyme and the Roche and Abbott platforms ( Figure 4A) . However, using the Roche or Abbott platforms to confirm IgG seropositive individuals, would have resulted in nearly 80% of reported seropositive individuals also having neutralization activity against SARS-CoV-2 ( Figure 4C ).

Confidence intervals for SARS-CoV-2 ID50 titers across the four different populations that were tested demonstrated significant overlap (Supplementary Table 2) , suggesting that individuals make comparable levels of neutralizing antibodies regardless of symptoms. One limitation of our cohort is that the length of symptom duration for the majority of these 164 individuals was not available, which could affect the neutralizing antibody response that an individual generates. The finding that 80% of twoplatform confirmed positive serology results have neutralizing activity is an important result, addressing a major concern when using COVID-19 serology to screen low disease prevalence populations. However, roughly 20% of the two-platform confirmed seropositive individuals did not have SARS-CoV-2 13 neutralization activity suggesting that a clinically validated SARS-CoV-2 neutralization assay is required for understanding if patients have protective immunity against COVID-19.

In principle, not all COVID-19 patients should have neutralizing antibodies, as these take time to develop after infection, and neutralizing antibodies represent a small subset of antibodies produced (30) . It is therefore encouraging that 84 of 87 specimens (96.6%) from SARS-CoV-2 PCR confirmed positive individuals also had neutralizing antibodies, and may encourage more aggressive steroid treatment in patients with symptoms of cytokine storm as production of neutralizing antibodies occurs shortly after infection. We note that the three specimens that did not have neutralizing antibodies were from different patients and these specimens were collected early in the disease process. One was collected two days before the patient became PCR positive and the other two were collected one day after the patient was confirmed positive using PCR. All three patients had neutralizing antibodies on the next specimen that was collected (day 3, 3, and 9). It is therefore important to consider symptom duration when testing for neutralizing antibodies as testing too early in the course of disease could lead to false negative results.

We explored using the median positive serology result as the cutoff value for determining the presence of neutralizing antibodies ( Figure 5 ). Specimens with serology results above the median were highly associated with neutralizing antibodies. 98.9, 95.1 and 83.5% of specimens above the median serology value contained neutralizing antibodies with ID50 titers greater than 50 when using the Diazyme, Abbott and Roche assays respectively.

We observed significant differences (P-value <0.005) in the demographics of 151 Diazyme seropositive individuals that were asymptomatic, mildly symptomatic, and hospital admitted. In particular, although the percentage of Hispanic individuals comprised 25.8% of this population, they accounted for 40% of the hospital admitted cases; of which 98% were PCR positive for COVID-19. This is similar to another recent report which observed that 60% of all pregnant women hospitalized for COVID-19 were of Hispanic ethnicity (37) .

The retrospective analysis of only the 164 seropositive SARS-CoV-2 individuals and not the population of 9530 individuals is a limitation of the study, preventing a fair comparison of the Diazyme platform with the Roche and Abbott SARS-CoV-2 serology platforms. This is because these individuals were effectively pre-screened for SARS-CoV-2 seropositivity before analysis on either the Roche or Abbott platforms.

Moreover, out of the 9,530 tests performed, the estimated overall false positive rate of the Diazyme IgG assay was between 0.7 -0.9%, and is equal to or lower than its published value of 0.9% (13) . This suggests that our findings would have been similar if either the Roche total Ig or Abbott IgG assays were used as the screening platform and not the confirmatory platform, as both assays have been reported to have specificity that exceeds 99% (14) (15) (16) ; emphasizing the dangers of using any one single serology platform to screen low prevalence populations for SARS-CoV-2 serology. Another limitation is that we did not use live virus to perform the neutralization assays, however, Rogers et al. showed a high correlation between the PSV and live virus, indicating that the use of a more hazardous live virus assay may be unnecessary (30) . A final limitation is that the 7 patients with other coronaviruses were not serologically tested for the presence of antibodies against these viruses and although they were PCR positive, it cannot be certain that a humoral response had occurred in these patients.

We report a comprehensive retrospective study of 164 SARS-CoV-2 seropositive specimens from 9,530 SARS-CoV-2 serology tests and demonstrate that serology results correlate with neutralization. Our study demonstrates the risk of using a single serology platform to identify SARS-CoV-2 seropositive individuals in low prevalence populations and highlights the benefits of a two-platform approach.

Finally, the inclusion of serology and neutralization activity found in mild and asymptomatic cases of COVID-19 are also unique, as cohorts used for other reports are generally of hospitalized patients. Fig. 1 . Flowcharts of the cohorts used for A) Main cohort, B) SARS-CoV-2 PCR positive cohort, and C) SARS-CoV-2 negative cohort. SNF, skilled nursing facility, RPNA, respiratory pathogen nucleic acid Fig. 2 . COVID-19 patients produce neutralization activity against SARS-CoV-2 and SARS-CoV-1. Percentage of specimens (N=87) from SARS-CoV-2 PCR confirmed patients (N=31, dark grey) and a SARS-CoV-2 negative patient cohort (N=100 specimens from 100 individuals, light grey) that had ID50 titers >50 against SARS-CoV-2 or SARS-CoV-1. 5 . Distribution of commercial serology platform results in specimens negative and positive for SARS-CoV-2 neutralization activity that initially screened positive by the Diazyme IgG assay. Median AU/mL, COI, and S/C values (Y-axis) on the Diazyme IgG, Roche total Ig, and Abbott IgG platforms, respectively, are shown in boxplots (whiskers are up to but no greater than 1.5 times the IQR) for specimens without (negative) or with (positive) ID50 neutralization titers against SARS-CoV-2 (X-axis). **** indicates significant difference between positive and negative group at a p value of <0.00001 by Mann-Whitney.

Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study

A Novel Coronavirus from Patients with Pneumonia in China

The socio-economic implications of the coronavirus pandemic (COVID-19): A review

Shut down and reboot-preparing to minimise infection in a post-COVID-19 era

Isolation, quarantine, social distancing and community containment: pivotal role for old-style public health measures in the novel coronavirus (2019-nCoV) outbreak

Economic Consequences of the COVID-19 Outbreak: the Need for Epidemic Preparedness

The outbreak of Coronavirus Disease 2019 (COVID-19)-An emerging global health threat

Waiting for Certainty on Covid-19 Antibody Tests -At What Cost?

Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses

On Natural and Artificial Vaccinations

Mouse-Pox (Infectious Ectromelia of Mice): A Review

Oral Poliovirus Vaccine: History of Its Development and Use and Current Challenge to Eliminate Poliomyelitis from the World

Longitudinal Monitoring of SARS-CoV-2 IgM and IgG Seropositivity to Detect COVID-19

Clinical performance of the Elecsys electrochemiluminescent immunoassay for the detection of SARS-CoV-2 total antibodies

Clinical Performance of the Roche SARS-CoV-2 Serologic Assay

Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in

Clinical And Analytical Performance Of An Automated Serological Test That Identifies S1/S2 Neutralizing IgG In COVID-19 Patients Semiquantitatively

Clinical evaluation of serological IgG antibody response on the Abbott Architect for established SARS-CoV-2 infection

Assessment of SARS-CoV-2 serological tests for the diagnosis of COVID-19 through the evaluation of three immunoassays: Two automated immunoassays (Euroimmun and Abbott) and one rapid lateral flow immunoassay (NG Biotech)

Multi-platform Comparison of SARS-CoV-2 Serology Assays for the Detection of COVID-19

Severe Acute Respiratory Syndrome Coronavirus 2−Specific Antibody Responses in Coronavirus Disease Patients

Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease

Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19)

Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis

Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2)

Virological assessment of hospitalized patients with COVID-2019

Performance of six SARS-CoV-2 immunoassays in comparison with microneutralisation

Broad neutralization of SARS-related viruses by human monoclonal antibodies

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

CDC. Information for Laboratories about Coronavirus

A Cluster of Cases of Severe Acute Respiratory Syndrome in Hong Kong

Identification of a Novel Coronavirus in Patients with Severe Acute Respiratory Syndrome

A Major Outbreak of Severe Acute Respiratory Syndrome in Hong Kong

Severe acute respiratory syndrome (SARS): a review of the history, epidemiology, prevention, and concerns for the future

Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections

Prevalence and Severity of Coronavirus Disease 2019 (COVID-19) Illness in Symptomatic Pregnant and Postpartum Women Stratified by Hispanic Ethnicity

We thank all of the staff in the UC San Diego Health clinical laboratories for their help identifying specimens for sensitivity and specificity testing. We also thank Amy Rockefeller and Ernestine Ferrer for valuable technical expertise. We would like to thank Waters Corporation (RTS) and Roche Diagnostics (MAH) for supporting the clinical chemistry fellowship at the University of California-San Diego.